Hypertension in pregnancy: diagnosis and management

on the use of the fullPIERS and PREP-S models.) There was no evidence on treatment initiation thresholds or target blood pressure levels for pre-eclampsia, so the committee based their recommendations on the NICE guideline on hypertension in adults and the values specified in the Control of Hypertension In Pregnancy Study (CHIPS; see evidence review A), which included women with chronic or gestational hypertension. There was some very limited evidence of both benefits and harms for different pharmacological interventions. However, as there was not enough evidence to recommend one treatment over another, the committee adopted the choices from the previous guideline and recommended choosing a treatment based on previous treatments, side- effect profiles and the woman's preferences. Labetalol is specifically licensed for use in pregnancy and so is suggested as the first-line option, with nifedipine as the next alternative, and methyldopa as the third option (as it may lead to more side effects and be the least effective option of the 3). There was limited evidence on the benefits and harms of planned early birth compared with expectant management of pregnancy in women with pre-eclampsia, so the committee recommended that decisions about timing of birth should be based on whether the
